{"entity":{"id":"nct05880394","kind":"trial","name":"Study of Dotatate Imaging in Breast Cancer","aka":[],"tldr":"A phase 2 trial of Gallium-68 DOTATATE in Breast cancer, run by Hoag Memorial Hospital Presbyterian, with a status the registry has not verified recently.","summary":"Study of Dotatate Imaging in Breast Cancer is a phase 2 interventional study registered as NCT05880394 by Hoag Memorial Hospital Presbyterian, with 30 participants planned, started 2023-01-10 and due to reach its primary completion in 2024-07-31. Interventions recorded: Gallium-68 DOTATATE, Copper-64 DOTATATE. Conditions recorded: Breast Cancer Stage IV.\n\nLinked to the drug Gallium-68 DOTATATE because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05880394","url":"https://clinicaltrials.gov/study/NCT05880394"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ga68-dotatate"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05880394","phase":"2","setting":"Somatostatin Receptor Imaging Study of Estrogen Receptor Positive (ER+) Metastatic Breast Cancer","sponsor":"Hoag Memorial Hospital Presbyterian","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05880394/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/"}]}}